{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462090141
| IUPAC_name = 1-Benzyl-2-piperazin-1-yl-1''H''-benzimidazole
| image = Lerisetron.svg
| width = 175

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 143257-98-1
| ATC_prefix = None
| ATC_suffix =
| PubChem = 65997
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 59389
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q36R82SXRG
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 56900

<!--Chemical data-->
| C=18 | H=20 | N=4 
| molecular_weight = 292.378 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWWDCRQZITYKDV-UHFFFAOYSA-N
| synonyms = F-0930-RS
}}

'''Lerisetron''' (code name '''F-0930-RS''') is a drug which acts as an [[Antagonist (pharmacology)|antagonist]] at the [[5-HT3 receptor|5-HT<sub>3</sub>]] [[Receptor (biochemistry)|receptor]].<ref>{{cite journal|last1=Orjales|first1=A|last2=Mosquera|first2=R|last3=Labeaga|first3=L|last4=Rodes|first4=R|title=New 2-Piperazinylbenzimidazole Derivatives as 5-HT<sub>3</sub> Antagonists. Synthesis and Pharmacological Evaluation|journal=Journal of Medicinal Chemistry|date=14 February 1997|volume=40|issue=4|pages=586-93|doi=10.1021/jm960442e|pmid=9046349|accessdate=3 October 2016}}</ref> It is a potent [[antiemetic]]<ref>{{cite journal|last1=Gomez-de-Segura|first1=IA|last2=Grande|first2=AG|last3=De Miguel|first3=E|title=Antiemetic Effects of Lerisetron in Radiation-Induced Emesis in the Dog|journal=Acta Oncologica|date=1998|volume=37|issue=7–8|pages=759–63|pmid=10050999|accessdate=3 October 2016}}</ref><ref>{{cite journal|last1=Cooper|first1=M|last2=Sologuren|first2=A|last3=Valiente|first3=R|last4=Smith|first4=J|title=Effects of Lerisetron, a New 5-HT<sub>3</sub> Receptor Antagonist, on Ipecacuanha-Induced Emesis in Healthy Volunteers|journal=Arzneimittel-Forschung|date=2002|volume=52|issue=9|pages=689–94|doi=10.1055/s-0031-1299952|pmid=12404884|accessdate=3 October 2016}}</ref> and was in [[clinical trial]]s for the treatment of nausea associated with cancer [[chemotherapy]].<ref>{{cite journal|last1=Huckle|first1=R|title=Lerisetron. FAES|journal=Current Opinion in Investigational Drugs|date=July 2003|volume=4|issue=7|pages=874–7|pmid=14619411|accessdate=3 October 2016}}</ref>

==See also==
* [[5-HT3 antagonist|5-HT<sub>3</sub> antagonist]]

== References ==
{{reflist}}

{{Serotonergics}}

[[Category:5-HT3 antagonists]]
[[Category:Antiemetics]]
[[Category:Benzimidazoles]]
[[Category:Piperazines]]

{{gastrointestinal-drug-stub}}